Industry

K.C. Pharmaceuticals Issues Voluntary Recall for Over 3 Million Bottles of Eye Drops Citing Sterility Concerns

Vision Monday7h ago1 min read

POMONA, Calif.—K.C. Pharmaceuticals, Inc., a manufacturer and private-label supplier of over-the-counter (OTC) eyecare products in North America, initiated a nationwide voluntary recall for more than 3 million bottles of eye drop products citing “lack of assurance of sterility,” according to the U.S. Food and Drug Administration (FDA). The FDA categorizes the recall as Class II, which is for products that may cause “temporary or medically reversible adverse health consequences,” where the probability of serious injury is remote. The recall of 3,111,072 bottles from eight product lines began on March 3, 2026, and was classified by the FDA on March 31.

Read full article on Vision Monday

AI Summary

Quick Take

K.C. Pharmaceuticals has initiated a nationwide voluntary recall of over 3.1 million bottles of over-the-counter eye drops across eight product lines due to a lack of sterility assurance. The FDA has designated this as a Class II recall, indicating that while the products may cause temporary or medically reversible adverse health consequences, the risk of serious injury is considered remote.

Why It Matters

This massive recall highlights ongoing vulnerabilities in the over-the-counter eye care supply chain, particularly regarding private-label manufacturing. While the Class II designation suggests a lower risk than recent high-profile contamination cases involving more severe pathogens, the sheer volume—over 3 million units—means these products are likely in many patients' medicine cabinets. For clinicians, this serves as a reminder to remain vigilant about unexplained ocular surface irritation and to proactively discuss the safety of generic OTC drops with patients.

Key Details

The recall involves 3,111,072 bottles of OTC eye care products spanning eight different product lines.
K.C. Pharmaceuticals is a major private-label supplier, meaning these products are frequently sold under various store-brand names across North America.
The FDA's Class II classification defines the risk as potentially causing temporary or medically reversible adverse health effects, with a remote probability of serious injury.
The recall process officially began on March 3, 2026, and received formal FDA classification on March 31, 2026.

Practice Implications

Clinicians should advise patients to check their current OTC eye drops for any products manufactured by K.C. Pharmaceuticals and discontinue use if they fall under the affected product lines. It is prudent to document any recent reports of ocular irritation or suspected infection that correlate with the use of generic drops. Practice owners should also ensure any retail inventory or in-office samples are screened against the recall list.

Who's Affected

OptometristsOphthalmologistsPractice OwnersPharmacistsRetail Eye Care Providers

What's Next

Patients and providers should monitor for further updates from the FDA regarding the specific brand names and lot numbers associated with the eight affected product lines. K.C. Pharmaceuticals is expected to address the underlying sterility assurance failures under continued regulatory oversight.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.